Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin
Research article published in Scientific reports (2017)
Abstract
Thrombin is a multifunctional enzyme with a key role in the coagulation cascade. Its functional modulation can culminate into normal blood coagulation or thrombosis. Thus, the identification of novel potent inhibitors of thrombin are of immense importance. Sculptin is the first specific thrombin inhibitor identified in the transcriptomics analysis of tick's salivary glands. It consists of 168 residues having four similar repeats and evolutionary diverged from hirudin. Sculptin is a competitive, specific and reversible inhibitor of thrombin with a Ki of 18.3 ± 1.9 pM (k on 4.04 ± 0.03 × 107 M-1 s-1 and k off 0.65 ± 0.04 × 10-3 s-1). It is slowly consumed by thrombin eventually losing its activity. Contrary, sculptin is hydrolyzed by factor Xa and each polypeptide fragment is able to inhibit thrombin independently. A single domain of sculptin alone retains ~45% of inhibitory activity, which could bind thrombin in a bivalent fashion. The formation of a small turn/helical-like structure by active site binding residues of sculptin might have made it a more potent thrombin inhibitor. In addition, sculptin prolongs global coagulation parameters. In conclusion, sculptin and its independent domain(s) have strong potential to become novel antithrombotic therapeutics.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin.
Warum dies für die Hirudotherapie relevant ist
Diese Studie charakterisiert Sculptin, einen neuartigen Thrombininhibitor aus der Transkriptomik von Speicheldrüsen von Zecken, als kompetitiven, spezifischen, reversiblen Inhibitor (Ki ~18,3 pM), der evolutionär von Hirudin divergiert und globale Gerinnungsparameter verlängert. Das Abstract unterscheidet, dass Thrombin Sculptin langsam verbraucht (wobei es letztlich seine Aktivität verliert), während Faktor Xa es hydrolysiert, wobei jedes Polypeptidfragment Thrombin unabhängig hemmen kann. Die Relevanz für ASH ist indirekt: Sculptin ist zecken- und nicht blutegelstämmig, obwohl es explizit mit Hirudin verglichen und im antithrombotischen therapeutischen Umfeld diskutiert wird. Einschränkung: Die Studie umfasst keine Blutegel und berichtet über Laborbefunde ohne klinische Daten.
Zitation
Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin
Iqbal A et al. · Scientific reports, 2017
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026